よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (92 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
59. Maraki S, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenemrelebactam in combination with aztreonam against multidrug-resistant, metallo-βlactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021.
40(8):1755-1759.
5
6
7
60. Falcone M, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Clin Infect Dis. 2021. 72(11):1871-1878.
8
9
10
61. Lodise TP, et al. Determining the optimal dosing of a novel combination regimen of
ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae
using a hollow-fibre infection model. J Antimicrob Chemother. 2020. 75(9):2622-2632.
11
12
13
62. Lodise TP, et al. Safety of Ceftazidime-Avibactam in Combination with Aztreonam
(COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. Antimicrob
Agents Chemother. 2022. 66(12):e0093522.
14
15
16
17
63. Tumbarello M, et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae
Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational
Multicenter Study. Clin Infect Dis. 2021 Nov 2;73(9):1664-1676. doi:
10.1093/cid/ciab176.
18
19
64. コリスチンの適正使用に関する指針―改訂版―, 日本化学療法学会. 2015. at
https://www.chemotherapy.or.jp/uploads/files/guideline/colistin_guideline_update.pdf.)
20
65. チゲサイクリン適正使用のための手引き 2014 日本化学療法学会雑誌. 2014. 62:311-66.
21
22
66. CLSI. Performance Stadards for Antimicrobial Susceptibility Testing. 35th ed. CLSI
supplement M100. Clinical and Laboratory Standards Institute; 2025.
23
24
67. Yano H. Nationwide genome surveillance of carbapenem-resistant Pseudomonas
aeruginosa in Japan. Antimicrob Agents Chemother. 2024. 68(5):e0166923.
25
26
27
68. Hishinuma T, et al. Emergence and spread of VIM-type metallo-β-lactamase-producing
Pseudomonas aeruginosa clinical isolates in Japan. J Glob Antimicrob Resist. 2020.
23:265-268.
28
29
30
69. Hishinuma T, et al. Spread of GES-5 carbapenemase-producing Pseudomonas
aeruginosa clinical isolates in Japan due to clonal expansion of ST235. PLoS One.
2018. 13(11):e0207134.
31
32
33
70. Pogue JM, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based
Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis.
2020. 71(2):304-310.
34
35
36
71. Almangour TA, et al. Ceftolozane-tazobactam vs. colistin for the treatment of infections
due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. J Glob
Antimicrob Resist. 2022. 28:288-294.
37
38
39
40
72. Motsch J, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial
Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in
Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 2020.
70(9):1799-1808.
41
42
43
73. Chen J, et al. Ceftazidime/Avibactam versus Polymyxin B in the Challenge of
Carbapenem-Resistant Pseudomonas aeruginosa Infection. Infect Drug Resist. 2022.
15:655-667.
92
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
59. Maraki S, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenemrelebactam in combination with aztreonam against multidrug-resistant, metallo-βlactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021.
40(8):1755-1759.
5
6
7
60. Falcone M, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Clin Infect Dis. 2021. 72(11):1871-1878.
8
9
10
61. Lodise TP, et al. Determining the optimal dosing of a novel combination regimen of
ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae
using a hollow-fibre infection model. J Antimicrob Chemother. 2020. 75(9):2622-2632.
11
12
13
62. Lodise TP, et al. Safety of Ceftazidime-Avibactam in Combination with Aztreonam
(COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. Antimicrob
Agents Chemother. 2022. 66(12):e0093522.
14
15
16
17
63. Tumbarello M, et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae
Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational
Multicenter Study. Clin Infect Dis. 2021 Nov 2;73(9):1664-1676. doi:
10.1093/cid/ciab176.
18
19
64. コリスチンの適正使用に関する指針―改訂版―, 日本化学療法学会. 2015. at
https://www.chemotherapy.or.jp/uploads/files/guideline/colistin_guideline_update.pdf.)
20
65. チゲサイクリン適正使用のための手引き 2014 日本化学療法学会雑誌. 2014. 62:311-66.
21
22
66. CLSI. Performance Stadards for Antimicrobial Susceptibility Testing. 35th ed. CLSI
supplement M100. Clinical and Laboratory Standards Institute; 2025.
23
24
67. Yano H. Nationwide genome surveillance of carbapenem-resistant Pseudomonas
aeruginosa in Japan. Antimicrob Agents Chemother. 2024. 68(5):e0166923.
25
26
27
68. Hishinuma T, et al. Emergence and spread of VIM-type metallo-β-lactamase-producing
Pseudomonas aeruginosa clinical isolates in Japan. J Glob Antimicrob Resist. 2020.
23:265-268.
28
29
30
69. Hishinuma T, et al. Spread of GES-5 carbapenemase-producing Pseudomonas
aeruginosa clinical isolates in Japan due to clonal expansion of ST235. PLoS One.
2018. 13(11):e0207134.
31
32
33
70. Pogue JM, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based
Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis.
2020. 71(2):304-310.
34
35
36
71. Almangour TA, et al. Ceftolozane-tazobactam vs. colistin for the treatment of infections
due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. J Glob
Antimicrob Resist. 2022. 28:288-294.
37
38
39
40
72. Motsch J, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial
Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in
Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 2020.
70(9):1799-1808.
41
42
43
73. Chen J, et al. Ceftazidime/Avibactam versus Polymyxin B in the Challenge of
Carbapenem-Resistant Pseudomonas aeruginosa Infection. Infect Drug Resist. 2022.
15:655-667.
92